Filtros de búsqueda

Lista de obras de Maurizio Scaltriti

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

artículo científico publicado en 2017

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

scientific article published on 13 January 2020

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

scientific article published on 20 April 2020

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

scientific article published on 13 July 2021

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study

scientific article published on 11 July 2019

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

scientific article published on 01 November 2019

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

scientific article published on 01 September 2019

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

scientific article published on 05 December 2019

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

scientific article published on 27 March 2020

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

artículo científico publicado en 2020

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

artículo científico publicado en 2009

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

scientific article published on 11 February 2019

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts

artículo científico publicado en 2020

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

artículo científico publicado en 2018

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

artículo científico publicado en 2018

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

artículo científico publicado en 2017

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

artículo científico publicado en 2020

Phase and context shape the function of composite oncogenic mutations

artículo científico publicado en 2020

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

artículo científico publicado en 2021

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

scientific article published on 12 August 2019

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

artículo científico publicado en 2016

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

artículo científico publicado en 2019

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

scientific article published on 01 October 2020

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda